AstraZeneca PLC (NASDAQ:AZN – Get Rating) – Investment analysts at Jefferies Financial Group cut their Q1 2022 earnings per share estimates for shares of AstraZeneca in a report issued on Tuesday, April 19th. Jefferies Financial Group analyst P. Welford now forecasts that the company will post earnings of $0.90 per share for the quarter, down from their prior estimate of $0.92. Jefferies Financial Group also issued estimates for AstraZeneca’s Q2 2022 earnings at $0.80 EPS, Q3 2022 earnings at $0.83 EPS, Q4 2022 earnings at $0.86 EPS and FY2026 earnings at $5.42 EPS.
Several other analysts also recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of AstraZeneca from £100 ($130.11) to £120 ($156.13) in a research report on Thursday, April 7th. Barclays lifted their price target on shares of AstraZeneca from £115 ($149.62) to £120 ($156.13) in a research report on Thursday, April 14th. Stifel Nicolaus initiated coverage on shares of AstraZeneca in a research report on Monday, February 28th. They issued a “buy” rating for the company. DZ Bank raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Friday, February 11th. Finally, Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating and set a $61.00 price target for the company in a research report on Tuesday, January 4th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $6,669.29.
AstraZeneca (NASDAQ:AZN – Get Rating) last announced its quarterly earnings data on Thursday, February 10th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.77 by $0.07. The company had revenue of $11.50 billion during the quarter, compared to the consensus estimate of $11.06 billion. AstraZeneca had a net margin of 0.30% and a return on equity of 27.48%. The company’s quarterly revenue was up 55.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.54 EPS.
The business also recently disclosed a semi-annual dividend, which was paid on Monday, March 28th. Shareholders of record on Friday, February 25th were paid a dividend of $0.985 per share. The ex-dividend date of this dividend was Thursday, February 24th. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.45. This represents a yield of 2.4%. AstraZeneca’s dividend payout ratio (DPR) is 1,378.67%.
A number of large investors have recently modified their holdings of AZN. MayTech Global Investments LLC bought a new position in AstraZeneca during the 3rd quarter valued at $25,000. Arlington Partners LLC bought a new position in AstraZeneca during the 4th quarter valued at $25,000. Horan Securities Inc. bought a new position in AstraZeneca during the 4th quarter valued at $26,000. Baltimore Washington Financial Advisors Inc. bought a new position in AstraZeneca during the 4th quarter valued at $27,000. Finally, Allegheny Financial Group LTD bought a new stake in shares of AstraZeneca during the 4th quarter worth $28,000. Institutional investors and hedge funds own 20.54% of the company’s stock.
About AstraZeneca (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- 3 Analyst Favorite Blue-Chip Stocks to Buy Now
- Does PNC Financial Stock Belong in Your Portfolio?
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.